Screening and Characterization of a Novel RNA Aptamer That Specifically Binds to Human Prostatic Acid Phosphatase and Human Prostate Cancer Cells

Molecules and Cells

Volumn 38, Issue 2, 2015, Pages 171-179

  Kong, Hoon Young ^a   Byun, Jonghoe ^a  

^a Dankook University   (South Korea)

Author keywords

Biomarker; Prostate cancer; Prostatic acid phosphatase; RNA aptamer

Indexed keywords

2' FLUOROPYRIMIDINE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANTINEOPLASTIC AGENT; APTAMER; FLUORESCENT DYE; FLUOROPYRIMIDINE DERIVATIVE; RNA; UNCLASSIFIED DRUG; ACID PHOSPHATASE;

ARTICLE; CONJUGATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMR-90 CELL LINE; IN VITRO SELECTION; LNCAP CELL LINE; MALE; NUCLEOTIDE SEQUENCE; PC-3 [HUMAN PROSTATE CARCINOMA] CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; RNA BINDING; RNA STABILITY; RNA STRUCTURE; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG SCREENING; ENZYMOLOGY; GENETICS; PROSTATE TUMOR; TUMOR CELL LINE;

ACID PHOSPHATASE; APTAMERS, NUCLEOTIDE; BINDING SITES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MODELS, MOLECULAR; PROSTATIC NEOPLASMS; SELEX APTAMER TECHNIQUE;

EID: 85003260886     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/MOLCELLS.2015.2272     Document Type: Article

References (52)

1. Azumi, N., Traweek, S.T., and Battifora, H. (1991). Prostatic acid phosphatase in carcinoid tumors. Immunohistochemical and immunoblot studies. Am. J. Surg. Pathol. 15, 785-790.
2. Bompiani, K.M., Woodruff, R.S., Becker, R.C., Nimjee, S.M., and Sullenger, BA. (2012). Antidote control of aptamer therapeutics: the road to a safer class of drug agents. Curr. Pharm. Biotechnol. 13, 1924-1934.
3. Bruno, J.G., Carrillo, M.P., Phillips, T., Vail, N.K., and Hanson, D. (2008). Competitive FRET-aptamer-based detection of methyl-phosphonic acid, a common nerve agent metabolite. J. Fluoresc. 18, 867-876.
4. Cary, K.C., and Cooperberg, M.R. (2013). Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther. Adv. Urol. 5, 318-329.
5. Chen, F., Hu, Y., Li, D., Chen, H., and Zhang, X.L. (2009) CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS One 4, e8142.
6. Chuang, T.D., Chen, S.J., Lin, F.F., Veeramani, S., Kumar, S., Batra, S.K., Tu, Y., and Lin, M.F. (2010). Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphory-lates ErbB-2 and regulates prostate cancer cell growth. J. Biol. Chem. 285, 23598-23606.
7. Ellington, A.D., and Szostak, J.W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822.
8. Eyetech Study Group. (2002). Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Reti-na 22, 143-152.
9. Fang, L.C., Dattoli, M., Taira, A., True, L., Sorace, R., and Wallner, K. (2008) Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy. Urology 71, 146-150.
10. Foy, J.W., Rittenhouse, K., Modi, M., and Patel, M. (2007). Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit. J. Ocul. Pharmacol. Ther. 23, 452-466.
11. Gerritsen, W.R. (2012). The evolving role of immunotherapy in prostate cancer. Ann. Oncol. 23, Suppl 8:viii22-27.
12. Gopinath, S.C. (2007). Methods developed for SELEX. Analytical and bioanalytical chemistry 387, 171-182.
13. Greene, K.L., Albertsen, P.C., Babaian, R.J., Carter, H.B., Gann, P.H., Han, M., Kuban, D.A., Sartor, A.O., Stanford, J.L., Zietman, A., et al. (2013). Prostate specific antigen best practice state-ment: 2009 update. J. Urol. 189 (1 Suppl), S2-S11.
14. Gunia, S., Koch, S., May, M., Dietel, M., and Erbersdobler, A. (2009). Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatecto-mies. Virchows. Arch. 454, 573-579.
15. Hamula, C.L., Le, X.C., and Li, X.F. (2011). DNA aptamers binding to multiple prevalent M-types of Streptococcus pyogenes. Anal. Chem. 83, 3640-3647.
16. Hassan, M.I., Aijaz, A., and Ahmad, F. (2010). Structural and func-tional analysis of human prostatic acid phosphatase. Expert Rev. Anticancer Ther. 10, 1055-1068.
17. Hong, H., Goel, S., Zhang, Y., and Cai, W. (2011). Molecular imaging with nucleic acid aptamers. Curr. Med. Chem. 18, 4195-4205.
18. Jayasena, S.D. (1999). Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 45, 1628-1650.
19. 2+. J. Inorg. Biochem. 82, 197-206.
20. Kong, H.Y., and Byun, J. (2013). Emerging roles of human prostatic acid phosphatase. Biomol. Ther. 21, 10-20.
21. Lin, M.F., Meng, T.C., Rao, P.S., Chang, C., Schonthal, A.H., and Lin, F.F. (1998). Expression of human prostatic acid phospha-tase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J. Biol. Chem. 273, 5939-5947.
22. Lin, M.F., Lee, M.S., Zhou, X.W., Andressen, J.C., Meng, T.C., Johansson, S.L., West, W.W., Taylor, R.J., Anderson, J.R., and Lin, F.F. (2001). Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J. Urol. 166, 1943-1950.
23. Liu, Z., Duan, J.H., Song, Y.M., Ma, J., Wang, F.D., Lu, X., and Yang, X.D. (2012). Novel HER2 aptamer selectively delivers cy-totoxic drug to HER2-positive breast cancer cells in vitro. J. Transl. Med. 10:148.
24. Lubaroff, D.M. (2012). Prostate cancer vaccines in clinical trials. Expert Rev. Vaccines 11, 857-868.
25. Madu, C.O., and Lu, Y. (2010). Novel diagnostic biomarkers for prostate cancer. J. Cancer 1, 150-177.
26. McNeel, D.G., Dunphy, E.J., Davies, J.G., Frye, T.P., Johnson, L.E., Staab, M.J., Horvath, D.L., Straus, J., Alberti, D., Marnocha, R., et al. (2009). Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27, 4047-4054.
27. Meng, L., Yang, L., Zhao, X., Zhang, L., Zhu, H., Liu, C., and Tan, W. (2012). Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. PLoS One 7, e33434.
28. Mosing, R.K., Mendonsa, S.D., and Bowser, M.T. (2005). Capillary electrophoresis-SELEX selection of aptamers with affinity for HIV-1 reverse transcriptase. Anal. Chem. 77, 6107-6112.
29. Oesterling, J.E., Suman, V.J., Zincke, H., and Bostwick, D.G. (1993). PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. North Am. 20, 687-693.
30. Ray, P., and White, R.R. (2010). Aptamers for targeted drug deli-very. Pharmaceuticals 3, 1761-1778.
31. Reiter, R.J., Tan, D.X., Manchester, L.C., Korkmaz, A., Fuentes-Broto, L., Hardman, W.E., Rosales-Corral, S.A., and Qi, W. (2013). A walnut-enriched diet reduces the growth of LNCaP human prostate cancer xenografts in nude mice. Cancer Invest. 31, 365-373.
32. Rockey, W.M., Huang, L., Kloepping, K.C., Baumhover, N.J., Gian-grande, P.H., and Schultz, M.K. (2011). Synthesis and radi-olabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg. Med. Chem. 19, 4080-4090.
33. Ruckman, J., Green, L.S., Beeson, J., Waugh, S., Gillette, W.L., Henninger, D.D., Claesson-Welsh, L., and Janjic, N. (1998). 2’-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556-20567.
34. Savla, R., Taratula, O., Garbuzenko, O., and Minko, T. (2011). Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin con-jugate for imaging and treatment of cancer. J. Control. Release 153, 16-22.
35. Sims, R.B. (2012). Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 30, 4394-4397.
36. Soares, N.D., Teodoro, A.J., Oliveira, F.L., Santos, C.A., Takiya, C.M., Junior, O.S., Bianco, M., Junior, A.P., Nasciutti, L.E., Fer-reira, L.B., et al. (2013). Influence of lycopene on cell viability, cell cycle, and apoptosis of human prostate cancer and benign hyperplastic cells. Nutr. Cancer 65, 1076-1085.
37. Song, Y., Zhu, Z., An, Y., Zhang, W., Zhang, H., Liu, D., Yu, C., Duan, W., and Yang, C.J. (2013). Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal. Chem. 85, 4141-4149.
38. Subramanian, N., Raghunathan, V., Kanwar, J.R., Kanwar, R.K., Elchuri, S.V., Khetan, V., and Krishnakumar, S. (2012). Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol. Vis. 18, 2783-2795.
39. Taira, A., Merrick, G., Wallner, K., and Dattoli, M. (2007). Reviving the acid phosphatase test for prostate cancer. Oncology 21, 1003-1010.
40. Talbot, L.J., Mi, Z., Bhattacharya, S.D., Kim, V., Guo, H., and Kuo, P.C. (2011). Pharmacokinetic characterization of an RNA apta-mer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery 150, 224-230.
41. Tang, Z., Parekh, P., Turner, P., Moyer, R.W., and Tan, W. (2009). Generating aptamers for recognition of virus-infected cells. Clin. Chem. 55, 813-822.
42. Thompson, I.M., Pauler, D.K., Goodman, P.J., Tangen, C.M., Lucia, M.S., Parnes, H.L., Minasian, L.M., Ford, L.G., Lippman, S.M., Crawford, E.D., et al. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350, 2239-2246.
43. Tuerk, C., and Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510.
44. Wallace, D.M., Chisholm, G.D., and Hendry, W.F. (1975). T.N.M. classification for urological tumours (U.I.C.C.)-1974. Br. J. Urol. 47, 1-12.
45. Walter, L.C., Bertenthal, D., Lindquist, K., and Konety, B.R. (2006). PSA screening among elderly men with limited life expectancies. JAMA 296, 2336-2342.
46. Wang, Y., Harada, M., Yano, H., Ogasawara, S., Takedatsu, H., Arima, Y., Matsueda, S., Yamada, A., and Itoh, K. (2005). Pros-tatic acid phosphatase as a target molecule in specific immuno-therapy for patients with nonprostate adenocarcinoma. J. Immu-nother. 28, 535-541.
47. Whitesel, J.A., Donohue, R.E., Mani, J.H., Mohr, S., Scanavino, D.J., Augspurger, R.R., Biber, R.J., Fauver, H.E., Wettlaufer, J.N., and Pfister, R.R. (1984). Acid phosphatase: its influence on the management of carcinoma of the prostate. J. Urol. 131, 70-72.
48. Zhang, Y., Hong, H., and Cai, W. (2011). Tumor-targeted drug delivery with aptamers. Curr. Med. Chem. 18, 4185-4194.
49. Zhang, M.Z., Yu, R.N., Chen, J., Ma, Z.Y., and Zhao, Y.D. (2012). Targeted quantum dots fluorescence probes functionalized with aptamer and peptide for transferrin receptor on tumor cells. Na-notechnology 23, 485104.
50. Zhu, G., Ye, M., Donovan, M.J., Song, E., Zhao, Z., and Tan, W. (2012). Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem. Commun. 48, 10472-10480.
51. Zimmermann, H. (2009). Prostatic acid phosphatase, a neglected ectonucleotidase. Purinergic Signal 5, 273-275.
52. Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415.